ArticleJournal of neuro-oncology2026
Early withdrawal of systemic corticosteroid following malignant glioma craniotomy: a real-world population-based cohort study.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundDexamethasone is commonly administered perioperatively in malignant glioma craniotomies to mitigate peritumoral edema and associated mass effects. However, prolonged steroid exposure impairs survival outcomes through immunosuppression. The optimal timing for postoperative steroid withdrawal remains unclear. This study investigates the association between early postoperative corticosteroid withdrawal and outcomes following malignant glioma craniotomy.
methodsA retrospective cohort analysis was conducted using the TriNetX database. Propensity score matching (PSM) was performed to form two balanced groups comparing patients with early steroid withdrawal (discontinuation of within 7 days postoperatively and no reinitiation within 3 months) versus late steroid withdrawal (any steroid use between 7 days and 3 months postoperatively). Primary outcomes were survival at 6 months, 1 year, and 2 years. Secondary outcomes included perioperative complications including meningitis, cerebrospinal fluid (CSF) leak, intracranial hemorrhage, venous thromboembolism, and early reoperation.
resultsA total of 34,693 patients were included in the crude cohort. After PSM, 5922 patients were included in both groups. Early withdrawal of corticosteroid was associated with improved survival (6 months: HR 0.57, p < 0.001, 1 year: HR 0.65, p < 0.001, 2 years: HR 0.70, p < 0.001). Additionally, early steroid withdrawal was associated with lower incidence of meningitis (1-month: 0.4% vs. 1.3%, p < 0.001; 6-month: 0.7% vs. 2.3%, p < 0.001), CSF leak (1-month: 0.6% vs. 1.5%, p < 0.001; 6-month: 0.9% vs. 2.5%, p < 0.001), intracranial hemorrhage (1-month: 2.2% vs. 2.8%, p = 0.041; 6-month: 3.8% vs. 5.5%, p < 0.001), venous thromboembolism (1-month: 2.4% vs. 4.6%, p < 0.001; 6-month: 4.5% vs. 9.3%, p < 0.001), and early reoperation (4.9% vs. 11.3%, p < 0.001).
conclusionsIn patients undergoing malignant glioma craniotomy, early postoperative steroids withdrawal was associated with improved survival and lower incidence of perioperative complications.
Indexed as
Identifiers
41712084What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.